Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Discover
Related topics
Intoducing cellenONE: The revolutionary Single Cell isolator
May 25, 2022
A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...
Advances in Leukemia research using shear flow and Bioflux system
May 24, 2022
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
May 4, 2022
A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Introducing IsoPlexis Single-Cell Natural Killer Panel
Mar 4, 2022
Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...
Enhanced small particle detection on CytekAurora and Northern Lights
Mar 2, 2022
Aurora system with ESP option, can fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...
Quantitative 3D Optical Imaging for Lago
Feb 21, 2022
Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...
Molecular imaging study design basics
Jan 31, 2022
By combining study design, study management, and image analytics in all major imaging modalities, BioLaurus has...
Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer
Nov 29, 2021
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
Accelerating AML Research Through Single-cell Multi-omics- integrate seamlessly into existing NGS
Nov 25, 2021
Dr. Linde Miles Memorial Sloan Kettering Cancer Center about her research, use of the Tapestri as a single-cell...
Dec 8, 2016
The use of patients' own cancer cells for in vitro selection of the most promising treatment is an attractive concept in personalized medicine. Human carcinoma cells from malignant pleural effusions (MPEs) are suited for this purpose since they have already adapted to the liquid environment in the patient and do not depend on a stromal cell compartment. Aim of this study was to develop a systematic approach for the in-vitro culture of MPEs to analyze the effect of chemotherapeutic as well as targeted drugs.
Methods: MPEs from patients with solid tumors were selected for this study. After morphological and molecular characterization, they were cultured in medium supplemented with patient-derived sterile-filtered effusion supernatant. Growth characteristics were monitored in real-time using the xCELLigence system. MPEs were treated with a targeted therapeutic (erlotinib) according to the mutational status or chemotherapeutics based on the recommendation of the oncologists. Results: We have established a robust system for the ex-vivo culture of MPEs and the application of drug tests in-vitro. The use of an antibody based magnetic cell separation system for epithelial cells before culture allowed treatment of effusions with only moderate tumor cell proportion. Experiments using drugs and drug-combinations revealed dose-dependent and specific growth inhibitory effects of targeted drugs.
Conclusions: We developed a new approach for the ex-vivo culture of MPEs and the application of drug tests in-vitro using real-time measuring of cell growth, which precisely reproduced the effect of clinically established treatments by standard chemotherapy and targeted drugs. This sets the stage for future studies testing agents against specific targets from genomic profiling of metastatic tumor cells and multiple drug-combinations in a personalized manner.
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com